SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA-Cancer J Clin 2011 61: 21236
  • 2
    Jeong IG, Ro JY, Kim SC et al. Extranodal extension in node-positive bladder cancer: the continuing controversy. BJU Int 2011; 108: 3843
  • 3
    Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001; 166: 1923
  • 4
    Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 66675
  • 5
    Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69: 6279
  • 6
    Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 4959; discussion 9–500
  • 7
    Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 45964; discussion 64–7
  • 8
    Paz-Ares L, Solsona E, Esteban E et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study (abstract #LBA4518). J Clin Oncol 2010; 28: 18s
  • 9
    Stöckle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995; 153: 4752
  • 10
    Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22: 27819
  • 11
    Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999; 161: 44954
  • 12
    Stein JP, Skinner DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am 2005; 32: 18797
  • 13
    Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 2006; 176: 537; discussion 7
  • 14
    Kassouf W, Agarwal PK, Herr HW et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008; 26: 1216
  • 15
    Kassouf W, Svatek RS, Shariat SF et al. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol 2011; doi:10.1097/00005392-199501000-00019. epub ahead of print
  • 16
    Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167: 12958
  • 17
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 14714
  • 18
    Eble JNSG, Epstein JI, Sesterhenn IA eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. Lyon, France: Lyon IARC Press, 2004
  • 19
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972 34: 187220
  • 20
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781
  • 21
    Schwarz G. Estimating the dimension of a model. Ann Stat 1978 6: 4614
  • 22
    Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005 92: 96570
  • 23
    Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005; 23: 235865
  • 24
    Cognetti F, Ruggeri EM, Felici A et al. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. J Clin Oncol 2008; 26 (Suppl.): abstract 5023